Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-2055
- Development stage
- Preclinical
- Lead developer
- Cypralis
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
CC-2055 is a novel, brain-penetrant, and selective small molecule cyclophilin D (CypD) antagonist developed by Cypralis. It is designed to inhibit calcium-mediated mitochondrial permeability transition pore (mPTP) opening by binding to CypD, thereby preventing mitochondrial dysfunction and apoptotic cell death. Preclinical studies in mouse models of epilepsy (such as the pilocarpine model) have demonstrated that CC-2055 exerts anti-seizure effects, reduces the frequency of spontaneous recurrent seizures, restores parvalbumin-positive (PV+) GABAergic interneurons in the CA1 hippocampus, and normalizes the resting membrane potential of CA1 pyramidal cells.
02
Targets
PPIF (Cyclophilin D)
Beyond the preview
Go deeper on CC-2055.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-2055.